Author

L. Teijeira

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

D. Escors· 2 shared G. Fernandez-Hinojal· 2 shared G. Kochan· 2 shared H. Arasanz· 2 shared M. J. Lecumberri· 2 shared R. Vera· 2 shared A. Bocanegra· 1 shared A. Fernandez· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Escors

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Functional systemic CD4 immunity is a differential factor for clinical responses to PD-L1/PD-1 blockade therapy in lung cancer

M. Zuazo, H. Arasanz, G. Fernandez-Hinojal, M. J. Garcia-Granda, M. Gato, A. Bocanegra, B. Hernandez, M. Martinez, L. Teijeira, I. Morilla, M. J. Lecumberri, A. Fernandez de Lascoiti, R. Vera, G. Kochan, D. Escors

This study identifies functional systemic CD4 immunity as a key predictor of response to PD-L1/PD-1 blockade therapy in lung cancer patients.

bioRxiv · Jan 9, 2019Cancer Biology

Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer

M. Zuazo-Ibarra, H. Arasanz, G. Fernandez-Hinojal, M. Gato-Canas, B. Hernandez-Marin, M. Martinez-Aguillo, M. J. Lecumberri, A. Fernandez, L. Teijeira, R. Vera, G. Kochan, D. Escors

The paper identifies baseline circulating highly-differentiated CD4 T cells as predictors of response or hyperprogression to PD-L1/PD-1 blockade therapy in lung cancer patients.

bioRxiv · May 22, 2018Cancer Biology